Australia markets closed

Crinetics Pharmaceuticals, Inc. (CRNX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
51.76-1.38 (-2.60%)
At close: 04:00PM EDT
52.91 +1.15 (+2.22%)
After hours: 06:56PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 4.15B
Enterprise value 3.34B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.58k
Price/book (mrq)4.99
Enterprise value/revenue 2.41k
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.64
52-week change 397.03%
S&P500 52-week change 330.69%
52-week high 355.78
52-week low 325.75
50-day moving average 351.98
200-day moving average 345.47

Share statistics

Avg vol (3-month) 3637.12k
Avg vol (10-day) 3592.26k
Shares outstanding 580.04M
Implied shares outstanding 682.12M
Float 874.6M
% held by insiders 12.08%
% held by institutions 1107.04%
Shares short (13 Sept 2024) 46.11M
Short ratio (13 Sept 2024) 412.75
Short % of float (13 Sept 2024) 47.80%
Short % of shares outstanding (13 Sept 2024) 47.64%
Shares short (prior month 15 Aug 2024) 46.47M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-20,747.62%

Management effectiveness

Return on assets (ttm)-28.27%
Return on equity (ttm)-47.66%

Income statement

Revenue (ttm)1.39M
Revenue per share (ttm)0.02
Quarterly revenue growth (yoy)-59.60%
Gross profit (ttm)N/A
EBITDA -276.18M
Net income avi to common (ttm)-258.54M
Diluted EPS (ttm)-3.76
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)862.95M
Total cash per share (mrq)10.78
Total debt (mrq)53.32M
Total debt/equity (mrq)6.42%
Current ratio (mrq)16.09
Book value per share (mrq)10.47

Cash flow statement

Operating cash flow (ttm)-178.33M
Levered free cash flow (ttm)-99.73M